Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc at JPMorgan Biotech Fireside Investor Series Transcript

Oct 12, 2023 / 05:00AM GMT
Release Date Price: $6.84 (-4.74%)
Operator

Welcome, and thank you for standing by. I would like to inform all participants that this conference call is being recorded and will be available to clients of JPMorgan. Parts of this conference call may also be reproduced in JPMorgan Research. If you have any objections, you may disconnect at this time. Press participants are not permitted on this call and should disconnect now.

Unless otherwise permitted by internal JPMorgan policy, members of JPMorgan investment and corporate banking are not permitted on this call and should disconnect now. Unless otherwise permitted by internal JPMorgan policy, members of JPMorgan investment and corporate banking are not permitted on this call and should disconnect now.

I would now like to turn the call over to Brian Cheng with JPMorgan. You may proceed.

Brian Cheng
JPMorgan Chase & Co. - Analyst

Thanks, Anna. Good afternoon, everyone. Thanks for joining us on our biotech call series at JPMorgan. I'm Brian Cheng, one of the senior biotech analysts here at the firm. For those of you who are live on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot